Skip to main content
. Author manuscript; available in PMC: 2010 Mar 4.
Published in final edited form as: Vaccine. 2009 Jan 23;27(10):1549–1556. doi: 10.1016/j.vaccine.2009.01.010

Table 1.

Assessment of anti-EEV NAb responses by comet-reduction assay.

Group Monkey Comet Reduction Scorea

Wk 0 Wk 4 Wk 13 Wk 30 Wk 48
rVV / rFPV 88M 0 + + + + + + + + + + +
90M 0 + + + + + + + + + +
91M 0 + + + + + + + + + + +
92M 0 + + + + + + + + +
95M 0 + + + + + + +
96M 0 + + + + + + + + +
rMVA / rFPV 80M 0 0 + + + +
81M 0 + + + + + + + +
82M 0 0 + + + +
83M 0 0 + + + + +
84M 0 0 + + + + +
87M 0 + + + + + + + +
rMVA / rMVA 001M 0 + + + + + + + + + +
002M 0 + + + + + + + + + +
003M 0 + + + + + + + + +
77M 0 0 + + + + + + + +
78M 0 + + + + + + + +
996L 0 + + + + + + + +

VIGb Control + + + - - - -
a

Plasma samples from individual monkeys were isolated following Prime 1 (Wk 4), Prime 2 (Wk 13), Boost 1 (Wk 30), or Boost 2 (Wk 48) and tested in a comet reduction assay at a 1:50 dilution. Matched pre-immune plasma (Wk 0) served as a negative control. The degree of comet reduction was scored as follows: 0, no reduction; +, some; ++, intermediate; +++, complete.

b

VIG was used as a positive control at 1:500 dilution.